Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO to set up Public...

    CDSCO to set up Public Relations Offices at all Zonal, Sub-Zonal Offices for regulator guidance

    Farhat NasimWritten by Farhat Nasim Published On 2019-12-15T13:42:11+05:30  |  Updated On 15 Dec 2019 1:42 PM IST

    New Delhi: In order to make regulatory guidance more accessible across the country, the nodal drug regulator, Central Drugs Standard Control Organisation (CDSCO) has decided to set up Public Relations Offices (PROs) at all Zonal and Sub-Zonal offices of CDSCO.


    The apex drug regulator has informed the stakeholders about the same through an order issued by the Drugs Controller General of India(DCGI), Dr VG Somani.


    The order mentioned that the PROs will be headed by concerned DDC(I)s/ADC(I)s/Head of offices with respect to the area of their working and act as 'Single Window. for disposal of grievances of stakeholder and shall also provide information to the innovators regarding regulatory requirements for development & commercialisation of their products and provide clarification pertaining to Drugs & Cosmetics Act 1940 and Rules, 1945.


    Also Read: CDSCO approves over 3000 global clinical trial sites, investigators; prepares comprehensive database


    The PROs will also be held responsible for guiding, assisting and handholding investors in various phases of the business life cycle as per the existing focus on 'Invest India/make in India'.


    The records and operation of these PROs will be maintained as per the procedure adopted by PRO at CDSCO headquarter.


    "They shall contact ADC(I). PRO at CDSCO Headquarter for any guidance in the matter," the order stated.


    "The stakeholders visiting the Public Relation Office shall not require any prior appointment and e-mail i.d./phone numbers of all zonal/sub-zonal offices may be utilised by them to communicate with respective PROs." the order added.


    CDSCO has further provided a process flow-chart for ready reference for handling applications/queries at Zonal and Sub-Zonal PROs. To view details of the flow chart click here.


    The Central Drugs Standard Control Organization (CDSCO) is the Central Drug Authority for discharging functions assigned to the Central Government under the Drugs and Cosmetics Act. CDSCO has six zonal offices, four sub-zonal offices, 13 port offices and seven laboratories under its control.

    Also Read: CDSCO directs Veterinary manufacturers to submit Periodic Safety Reports every 6 months for first 2 years

    CDSCOCentral Drugs Standard Control Organisationcsdco zonal officeDCGIDrugs Controller General of Indiapropublic relations officerspublic relations officesregulatory guidanceVG Somani

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok